Claims for Patent: 7,709,506

Summary for Patent: 7,709,506

Title:	Nicotinamide derivatives useful as p38 inhibitors
Abstract:	Compounds of formula (I): ##STR00001## are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38.
Inventor(s):	Aston; Nicola Mary (Stevenage, GB), Bamborough; Paul (Stevenage, GB), Walker; Ann Louise (Stevenage, GB)
Assignee:	GlaxoSmithkline LLC (Philadelphia, PA)
Application Number:	11/462,851
Patent Claims:	1. A method for treating pain as a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase comprising administering to a patient in need thereof a compound of formula (I): ##STR00061## wherein R.sup.1 is selected from hydrogen, C.sub.1-6alkyl optionally substituted by up to three groups selected from C.sub.1-6alkoxy, halogen and hydroxy, C.sub.2-6alkenyl, C.sub.3-7cycloalkyl optionally substituted by one or more C.sub.1-6alkyl groups, phenyl optionally substituted by up to three groups selected from R.sup.5 and R.sup.6, and heteroaryl optionally substituted by up to three groups selected from R.sup.5 and R.sup.6, R.sup.2 is selected from hydrogen, C.sub.1-6alkyl and --(CH.sub.2).sub.q--C.sub.3-7cycloalkyl optionally substituted by one or more C.sub.1-6alkyl groups, or (CH.sub.2).sub.mR.sup.1 and R.sup.2, together with the nitrogen atom to which they are bound, form a four- to six-membered heterocyclic ring optionally substituted by up to three C.sub.1-6alkyl groups; R.sup.3 is chloro or methyl; R.sup.4 is the group --NH--CO--R.sup.7 or --CO--NH--(CH.sub.2).sub.q--R.sup.8; R.sup.5 is selected from C.sub.1-6alkyl, C.sub.1-6alkoxy, --(CH.sub.2).sub.q--C.sub.3-7cycloalkyl optionally substituted by one or more C.sub.1-6alkyl groups, --CONR.sup.9R.sup.10, --NHCOR.sup.10, --SO.sub.2NHR.sup.9, --(CH.sub.2).sub.sNHSO.sub.2R.sup.10, halogen, CN, OH, --(CH.sub.2).sub.sNR.sup.11R.sup.12, and trifluoromethyl; R.sup.6 is selected from C.sub.1-6alkyl, C.sub.1-6alkoxy, halogen, trifluoromethyl and --(CH.sub.2).sub.sNR.sup.11R.sup.12; R.sup.7 is selected from hydrogen, C.sub.1-6alkyl, --(CH.sub.2).sub.q--C.sub.3-7cycloalkyl optionally substituted by one or more C.sub.1-6alkyl groups, trifluoromethyl, --(CH.sub.2).sub.rheteroaryl optionally substituted by R.sup.13 and/or R.sup.14, and --(CH.sub.2).sub.rphenyl optionally substituted by R.sup.13 and/or R.sup.14; R.sup.8 is selected from hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl optionally substituted by one or more C.sub.1-6alkyl groups, CONHR.sup.9, phenyl optionally substituted by R.sup.13 and/or R.sup.14, and heteroaryl optionally substituted by R.sup.13 and/or R.sup.14; R.sup.9 and R.sup.10 are each independently selected from hydrogen and C.sub.1-6alkyl, or R.sup.9 and R.sup.10, together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N--R.sup.15, wherein the ring may be substituted by up to two C.sub.1-6alkyl groups; R.sup.11 is selected from hydrogen, C.sub.1-6alkyl and --(CH.sub.2).sub.q--C.sub.3-7cycloalkyl optionally substituted by one or more C.sub.1-6alkyl groups, R.sup.12 is selected from hydrogen and C.sub.1-6alkyl, or R.sup.11 and R.sup.12, together with the nitrogen atom to which they are bound, form a five or six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N--R.sup.15; R.sup.13 is selected from C.sub.1-6alkyl, C.sub.1-6alkoxy, --(CH.sub.2).sub.q--C.sub.3-7cycloalkyl optionally substituted by one or more C.sub.1-6alkyl groups, --CONR.sup.9R.sup.10, --NHCOR.sup.10, halogen, CN, --(CH.sub.2).sub.sNR.sup.11R.sup.12, trifluoromethyl, phenyl optionally substituted by one or more R.sup.14 groups and heteroaryl optionally substituted by one or more R.sup.14 groups; R.sup.14 is selected from C.sub.1-6alkyl, C.sub.1-6alkoxy, halogen, trifluoromethyl and --NR.sup.11R.sup.12; R.sup.15 is selected from hydrogen and methyl; X and Y are each independently selected from hydrogen, methyl and halogen; Z is halogen; m is selected from 0, 1, 2, 3 and 4, wherein each carbon atom of the resulting carbon chain may be optionally substituted with up to two groups selected independently from C.sub.1-6alkyl and halogen; n is selected from 0, 1 and 2; q is selected from 0, 1 and 2; r is selected from 0 and 1; and s is selected from 0, 1, 2 and 3; or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1 wherein R.sup.1 is selected from C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.3-7cycloalkyl optionally substituted by one or more C.sub.1-6alkyl groups, phenyl optionally substituted by up to three substituents selected from R.sup.5 and R.sup.6, heteroaryl optionally substituted by up to three substituents selected from R.sup.5 and R.sup.6. 3. The method according to claim 1 wherein R.sup.2 is hydrogen. 4. The method according to claim 1 wherein R.sup.3 is methyl. 5. The method according to claim 1 wherein X is fluorine. 6. The method according to claim 1 wherein R.sup.7 is selected from C.sub.1-6alkyl, --(CH.sub.2).sub.q--C.sub.3-7cycloalkyl, trifluoromethyl, --(CH.sub.2).sub.rheteroaryl optionally substituted by R.sup.13 and/or R.sup.14, and --(CH.sub.2).sub.rphenyl optionally substituted by C.sub.1-6alkyl, C.sub.1-6alkoxy, --(CH.sub.2).sub.q--C.sub.3-7cycloalkyl, --CONR.sup.9R.sup.10, --NHCOR.sup.10, halogen, CN, trifluoromethyl, phenyl optionally substituted by one or more R.sup.14 groups and/or heteroaryl optionally substituted by one or more R.sup.14 groups. 7. The method according to claim 1 wherein R.sup.8 is selected from C.sub.3-7cycloalkyl, CONHR.sup.9, heteroaryl optionally substituted by R.sup.13 and/or R.sup.14, and phenyl optionally substituted by C.sub.1-6alkyl, C.sub.1-6alkoxy, --(CH.sub.2).sub.q--C.sub.3-7cycloalkyl, --CONR.sup.9R.sup.10, --NHCOR.sup.10, halogen, CN, trifluoromethyl, phenyl optionally substituted by one or more R.sup.14 groups and/or heteroaryl optionally substituted by one or more R.sup.14 groups. 8. The method according to claim 1 wherein the compound of Formula (I) is 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl- )-nicotinamide, or a pharmaceutically acceptable salt thereof. 9. The method according to claim 1 wherein the compound of Formula (I) is 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl- )-nicotinamide. 10. The method according to claim 1 wherein the compound of Formula (I) is administered in a pharmaceutical composition comprising an effective amount of a compound, or a pharmaceutically acceptable salt thereof according to Formula (I), in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients. 11. The method according to claim 1 wherein the condition of pain is selected from the group consisting of chronic pain, neuromuscular pain, headache, cancer pain, acute and chronic inflammatory pain associated with osteoarthritis and rheumatoid arthritis, post operative inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia, inflammatory neuropathies and migraine pain. 12. The method according to claim 1 wherein the compound of Formula (I) is optionally in combination with a second therapeutic agent. 13. The method according to claim 12 wherein the combination therapy of a compound of Formula (I) and the second therapeutic agent are administered together or separately. 14. The method according to claim 13 wherein the compound of Formula (I) and the second therapeutic agents are administered separately or sequentially in any order. 15. The method according to claim 12 wherein the second therapeutic agent is an immunosuppressant, an anti-TNF.alpha. agent, a tyrosine kinase inhibitor, a kallikrein antagonist, an interleukin 11 agonist, an interferon beta 1 agonist, a hyaluronic acid agonist, a matrix metalloprotease inhibitor, and other disease modifying anti-rheumatic drugs (DMARDs). 16. The method according to claim 15 wherein the immunosuppressant is selected from amtolmetin guacil, mizoribine and rimexolone; the anti-TNF.alpha. agent is selected from etanercept, infliximab, diacerein; the tyrosine kinase inhibitor is leflunomide; the matrix metalloprotease inhibitor is cipemastat; and the DMARD agents are selected from methotrexate, sulphasalazine, cyclosporin A, hydroxychoroquine, auranofin, aurothioglucose, gold sodium thiomalate and penicillamine. 17. The method according to claim 15 wherein the second therapeutic agent is selected from etanercept, infliximab, diacerein; leflunomide; methotrexate, sulphasalazine, cyclosporin A, hydroxychoroquine, auranofin, aurothioglucose, gold sodium thiomalate and penicillamine. 18. The method according to claim 1 wherein the dose of a compound of Formula (I) in a human is from about 0.1 mg/kg to 10 mg/kg. 19. The method according to claim 8 wherein the dose is from about 0.1 mg/kg to 10 mg/kg. 20. The method according to claim 9 wherein the dose is from about 0.1 mg/kg to 10 mg/kg. 21. The method according to claim 11 wherein the compound of Formula (I) is 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpro- pyl)-nicotinamide, or a pharmaceutically acceptable salt thereof. 22. The method according to claim 11 wherein the compound of Formula (I) is 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpro- pyl)-nicotinamide. 23. A method of treating chronic pain, neuromuscular pain, headache, cancer pain, acute and chronic inflammatory pain associated with osteoarthritis or rheumatoid arthritis, post operative inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia, inflammatory neuropathies or migraine pain in a patient in need thereof, comprising administering to said patient an effective amount of a compound 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl- )-nicotinamide, or a pharmaceutically acceptable salt thereof. 24. The method according to claim 23 wherein the compound is of 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-N-(2,2-dimethylpropyl- )-nicotinamide. 25. The method according to claim 24 wherein the patient is a human and the effective amount of the compound administered to said human is from about 0.1 mg/kg to 10 mg/kg. 26. The method according to claim 23 wherein the treatment is chronic pain. 27. The method according to claim 23 wherein the treatment is cancer pain. 28. The method according to claim 23 wherein the treatment is acute and chronic inflammatory pain associated with osteoarthritis or rheumatoid arthritis. 29. The method according to claim 23 wherein the treatment is post operative inflammatory pain. 30. The method according to claim 23 wherein the treatment is neuropathic pain. 31. The method according to claim 23 wherein the treatment is diabetic neuropathy. 32. The method according to claim 23 wherein the treatment is trigeminal neuralgia, post-hepatic neuralgia or inflammatory neuropathy. 33. The method according to claim 23 wherein the treatment is headache or migraine pain. 34. The method according to claim 23 wherein the treatment is neuromuscular pain.

Details for Patent 7,709,506

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2022-02-12
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2022-02-12
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2022-02-12
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2022-02-12
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2022-02-12
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2022-02-12
Immunex Corporation	ENBREL	etanercept	Injection	103795			2022-02-12